



Accelerating the impacts of metabolomics in regulatory toxicology – an academic view


RSC / IGHRC Joint Awareness Day, London 13 October 2017

> Professor Mark Viant University of Birmingham, UK

> > ©University of Birmingham

Overview of presentation

- Metabolomics is a mature science in academia, but less so in regulatory toxicology
- Five thoughts on Why?
- Case studies in metabolomics
 - Discovering MoA (and an endpoint for a regulated bioassay?)
 - Insights into toxicokinetics
- Progress on Best Practice guidelines for regulatory metabolomics
- Accessibility to metabolomics tools



Metabolomics is a mature science in academia

<u>Community</u>: large International Metabolomics Society, with national affiliates, extensive conference programs, scientific working groups...

<u>Data</u>: European Bioinformatics Institute's MetaboLights database, fastest growing of all 'omics databases at EBI

Publications: >59,000, several in Science and Nature (Web of Science, 2017)

Journals: Metabolomics, Metabolites, Journal of Metabolomics...

Investment: US NIH invested \$111 million (2012-17)

Outreach: first Massive Open Online Course (MOOC) >6,000 registrants

<u>Scale</u>: Global market expected to reach \$3.5 billion by 2021 (https://www.mordorintelligence.com/industry-reports/global-metabolomics-market-industry)

Metabolomics is a mature science ... particularly *in human disease*




The International Phenome [Metabolomics] Centre Network is a research consortium working to transform health care globally and improve disease prevention, detection and treatment by understanding disease mechanisms

Includes more than a dozen international partners with hubs in: Australia, Canada, China, Japan, Singapore, Taiwan, the United States, and the United Kingdom

www.birmingham.ac.uk/phenome-centre

What *major activity* in metabolomics and toxicology?

- 2002-05, Consortium for Metabonomic Toxicology (COMET)
- Led by Jeremy Nicholson, Imperial College London and five pharmaceutical companies
- Objective: to generate a metabolomics database using ¹H
 NMR spectroscopy of rodent urine and serum and to build a predictive expert system for target organ toxicity in rat
- >10 publications
- Reported as highly successful



e.g. J. Proteome Res., 2007, 6:4407-22

What *major activity* in metabolomics and toxicology?


- BASF's metabolomics program
- Led by Ben van Ravenzwaay with Metanomics Health
- Constructed a metabolomics database using mass spectrometry of rat serum, discovering numerous metabolome patterns for different toxicological targets
- Example: Metabolomics: A tool for early detection of toxicological effects and an opportunity for biology based grouping of chemicals—From QSAR to QBAR Mutation Research 2012, 746:144–50
- >600 chemicals studied, >10 publications
- Database not open access

423 publications: topic of metabolomics and toxicology


Citation Report: 423

(from Web of Science Core Collection)

You searched for: **TOPIC:** ((metabolomic* or metabonomic*) and toxicology)



Published Items in Each Year



Citations in Each Year

Why isn't metabolomics already widely used in regulatory toxicology?

Key question – do the regulatory agencies have any interest in metabolomics?

Regulators are very interested in metabolomics

ECHA: New Alternative Methods (NAM) workshop report, April 2016

"Conclusions: NAM data from metabolomics have provided a robust and interpretable basis for the mechanism of action which has supported the hypothesis of category membership and facilitates read-across"

UK Health & Safety Executive: Prof George Loizou, Animal-Free Chemical Safety Assessment (Frontiers in Pharmacology 2016; 7:218)

- "Metabolomics... has the advantage of being high-throughput and currently provides the best approach to delineating and understanding a biological mechanism preceding an effect"
- <u>EFSA</u>: Jean Lou Dorne, Modern methodologies and tools for human hazard assessment of chemicals (*EFSA Journal* 2014; 12:3638)
- "In the future, publicly available databases combining in vitro and in vivo OMIC datasets for large databases of compounds with MoA/AOP knowledge will help considerably to a) identify biomarkers associated with specific AOPs, and b) to bring new tools for predictive toxicology.

What are roadblocks to using metabolomics in regulatory context? (1)

1. Lack of relevant, appropriately designed, sufficiently large, open-access metabolomics case studies that address a regulatory (not academic) purpose

2. Lack of Best Practice guidelines for conducting a regulatory metabolomics study and lack of validation and reporting standards

ECHA NAM workshop – "There are a number of R&D needs including a database to support metabolomics, standardisation, validation and reporting formats." (2016)

What are roadblocks (and progress) to using metabolomics in regulatory context? (2)

- 3. Accessibility to metabolomics tools (analytical and computational)
 - Commercial service providers, Phenome Centres, etc.
 - Open-access workflows: W4M, EU PhenoMeNal, etc. (using Galaxy)
- Lack of education and training courses in (regulatory) metabolomics, both 'awareness training' and 'hands-on training'
 - Birmingham Metabolomics Training Centre provided 2-days of omics training to ECHA (www.birmingham.ac.uk/bmtc)
- 5. Robust metabolite identification
 - Academic pursuit!
 - Metabolite ID and Model Organism Metabolomes Task Groups of International Metabolomics Society, etc.

 Lack of relevant, appropriately designed, sufficiently large, open-access metabolomics case studies that address a regulatory (not academic) purpose

Examples...

- Enhancing chemical grouping and read-across
- Deriving points of departure for hazard assessment
- Discovering MoA(s), e.g. to identify new bioassays for screening


Strengths of metabolomics – highlighted in following examples

- [Not unique] Shares several strengths with complementary omics techniques: non-targeted, highly effective at discovery science, e.g. insights into MoA, guiding selection of bioassays for screening
- [Unique] Measures actual cellular function; metabolites can be causally associated with apical endpoints and adverse outcomes
- [Unique] Potential to measure simultaneously the exposure chemical and its metabolites (toxicokinetics) <u>and</u> the disruption to cell/organism's endogenous metabolism

Discovering MoA (and an endpoint for a regulated bioassay?) using metabolomics


Adverse Outcome Pathway

relevance




Can metabolomics discover molecular markers that are predictive of adverse outcome at an organism (or higher) level?

Power of metabolomics for initial discovery



Translating the discovery to regulatory toxicology


Relevance



©University of Birmingham

Take home messages from ZnO study


- Metabolomics discovered novel mechanism of toxicity of ZnO nanoparticles that disrupts predator-prey signalling; ecological implications still to be determined
- Technologies exist for translating this 'metabolic Key Event' to a validated regulatory assay



- Two species AOP !?


Insights into toxicokinetics using metabolomics

Effect of AChE inhibitor




Southam et al., Environ Sci Technol 45:3759-3767 (2011)

Desmethyl fenitrothion and S-methyl-GSH both detected by mass spectrometry metabolomics



Fenitrothion metabolism



©University of Birmingham

2. Lack of Best Practice guidelines for conducting a regulatory metabolomics study and lack of validation and reporting standards

Progress in best practice, validation, reporting standards

MEtabolomics standaRds Initiative in Toxicology (MERIT)

- Developing best-practice guidelines and minimal reporting standards for the acquisition, processing and analysis of metabolomics data
- Funded by ECETOC, with industry, government and academic scientists

OECD Extended Advisory Group on Molecular Screening & Toxicogenomics

• Developing Transcriptomics Reporting Framework (co-led by Tim Gant), Metabolomics Reporting Framework, ...

3. Accessibility to metabolomics tools (analytical and computational)

A complete workflow for high-resolution spectral-stitching nanoelectrospray direct-infusion mass-spectrometry-based metabolomics and lipidomics

Andrew D Southam^{1,3}, Ralf J M Weber^{1,3}, Jasper Engel², Martin R Jones¹ & Mark R Viant^{1,2}


¹School of Biosciences, University of Birmingham, Birmingham, UK. ²NERC Biomolecular Analysis Facility – Metabolomics Node (NBAF-B), School of Biosciences, University of Birmingham, UK. ³These authors contributed equally to this work. Correspondence should be addressed to M.R.V. (m.viant@bham.ac.uk).

NATURE PROTOCOLS | VOL.12 NO.2 | 2016 | 255









Galaxy is intuitive to use and highly flexible allowing non-programmers to create workflows


FAIR data – Findable, Accessible, Interoperable, Reusable



Take home messages

- There are several challenges to applying metabolomics in regulatory toxicology:
 - 1. Relative lack of robust case studies in regulatory metabolomics
 - Lack of best practice, reporting frameworks, and 'awareness training'

 Metabolomics is a mature science in academia, the roadblocks are being addressed, and efforts to translate this technology towards regulatory toxicology should now be accelerated Accelerated while engaging all parties...



Metabolomics @ University of Birmingham













©University of Birmingham